EUCTR2021-001029-32-DE进行中（未招募）1 期
A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 91
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject has one of the following solid tumors which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists (subjects who have received a prior TRK inhibitor may be eligible after progression or intolerance of therapy):
- •NTRK-fusion-positive, locally advanced (i.e., not amenable to surgical resection) or metastatic solid tumor
- •NTRK-gene amplified, locally advanced or metastatic solid tumor
- •(Phase 1 only)
- •EWSR1-WT1-positive DSRCTs (Phase 1 only)
- •Note: Subjects with any grade of glioma previously treated with systemic therapy and documented NTRK gene fusion or amplification are eligible.
- •For phases 1 and 2, subject's prior treatment should include all approved regimens that have demonstrated a survival advantage for the subject's disease, stage, and line of therapy.
- •2. Phase 1
- •Subjects with NTRK-fusion-positive solid tumors other than primary brain tumors (non-brain primary tumors) must have previously received treatment with a TRK inhibitor, unless the subject does not have access to TRK-inhibitor therapy (e.g., no TRK inhibitor is marketed and available to the subject in the subject's country) or unless the subject is ineligible for marketed TRK-inhibitor therapy (e.g., subject has a resistance mutation).
- •Subjects with NTRK-gene-amplified solid tumors, primary brain tumors or EWSR1-WT1- positive DSRCTs may have received prior treatment with a TRK inhibitor but this is not required.
- •3. Phase 2
- •Has measurable disease by RECIST v1.1 for subjects with non-brain primary tumors or RANO criteria for subjects with primary brain tumors.
- •Subjects with non-brain primary tumors must have previously received treatment with a TRK inhibitor and must have a documented on-target resistance mutation(s) (e.g., solvent front, gatekeeper or xDFG mutation) as the mechanism of resistance to their prior TRK-inhibitor treatment based on a tumor biopsy obtained following their most recent systemic therapy. Archival tissue from a prior biopsy taken after the subject completed TRK-inhibitor treatment but prior to additional systemic therapy may be used to meet this eligibility criterion.
- •Subjects with primary brain tumors may have received prior treatment with a TRK inhibitor but this is not required. For these subjects, a tumor biopsy any time following TRK-inhibitor treatment is encouraged, and if analyzed for resistance mechanisms, must demonstrate an on-target resistance mutation (e.g. solvent front, gatekeeper or xDFG mutation) as the mechanism of resistance to their prior TRK-inhibitor treatment.
- •However, biopsies of brain tumors are not required for eligibility.
- •Note: Subjects with NTRK-gene amplified tumors or EWSR1-WT1- positive DSRCTs are not eligible in Phase 2.
- •4. Subjects with brain tumors and brain metastasis must be neurologically stable. Subjects with asymptomatic brain metastases are eligible.
- •5. Age = 18 years at the time of signing the informed consent form (ICF).
- •6. Has provided written informed consent.
- •7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.
- •8. Acceptable liver, renal, hematologic, and coagulation function
- •Bilirubin = 1.5x ULN
- •AST, ALT = 3.0x ULN
- •Estimated creatinine clearance of = 45 ml/min based on the Cockcroft-
- •Gault formula
- •Absolute neutrophil count = 1000/mm3
- •Platelet count = 75,000/mm3
- •Hemoglobin = 8 g/dL
- •INR = 1.5 ULN and aPTT = 1.5 ULN. Study subjects on therapeutic dose
排除标准
- •1. Cytotoxic chemotherapy, biologic agent, or radiation therapy = 3 weeks prior to the first dose of study treatment (6 weeks for nitrosoureas). The
- •interval may be reduced to 2 weeks for bone-only radiation therapy or investigational agents not expected to be associated with AEs after 2
- •weeks of last administration.
- •Subjects with either primary brain tumors or brain metastasis who require radiation must have completed brain radiation therapy at least
- •12 weeks prior to the brain MRI obtained within 4 weeks of the first dose of study treatment. The Medical Monitor should be consulted if there is an interval of less than 12 weeks if there is reasonable certainty of radiographic disease progression (e.g., new disease outside the radiation therapy field following completion of the radiation therapy) or histopathologic documentation of unequivocal disease progression. Subjects with asymptomatic brain metastases are not required to have received radiation therapy.
- •2. Small-molecule kinase inhibitors or hormonal agents = 14 days or within 5 half-lives prior to the first dose of study treatment, whichever is shorter.
- •3. For subjects enrolled in Phase 2: Treatment with more than one prior TRK inhibitor.
- •Note: Subjects enrolled in the Phase 1 part of the study may have received more than one TRK inhibitor.
- •4. Clinically significant AEs that have not returned to baseline or = Grade 1 based on NCI CTCAE v5.0.
- •5. Major surgery = 6 weeks or minor surgery = 14 days prior to the first dose of study treatment
- •6. Clinically significant intercurrent disease including but not limited to:
- •New York Heart Association Class III or IV heart failure
- •Myocardial infarction or stroke = 26 weeks prior to the first dose of study treatment
- •Unstable angina within = 13 weeks prior to the first dose of study treatment unless the underlying disease has been corrected by procedural
- •intervention e.g., stent, bypass
- •Severe aortic stenosis
- •Uncontrolled arrhythmia.
- •Congenital long QT syndrome.
- •QTc > 470 milliseconds by Fredericia criteria (QTcF) based on the average of 3 ECGs taken approximately 1 minute apart and all within 10
- •minutes of each other. The subject should be reclining for 5 minutes prior to ECGs. Local readings may be used for this inclusion criterion.
- •Clinically significant active infection requiring systemic antibiotic, antiviral or antifungal medication. Subjects must be medically stable,
- •afebrile, no documented evidence of ongoing infection and not taking antimicrobial treatment for = 3 days prior to the first dose of study treatment
- •7. Subjects taking sensitive substrates of CYP2B6, CYP2C8, CYP2C9 and CYP3A unless the subject can safely discontinue these medications or
- •change to comparable medications that are not sensitive substrates of these CYPs.
- •8. Subjects that are taking strong CYP3A inhibitors or inducers unless the subject can safely discontinue these medications or change to
- •comparable medications that are not strong inhibitors or inducers of CYP3A at least 5 half-lives or 7 days prior to the first dose of study treatment.
- •9. Human immunodeficiency virus (HIV) infection.
- •10. Active hepatitis B or C infection.
- •11. Previous or concurrent cancer that is distinct in the primary site or histology from the solid tumors under evaluation within 3 years before
- •start of study treatment except for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors (Ta [noninvasive tumor], Tis [carcinoma
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid TumorsOne of the following solid tumors which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists:• NTRK-fusion-positive, locally advanced (i.e., not amenable to surgical resection) or metastatic solid tumor• NTRK-gene amplified, locally advanced or metastatic solid tumor (Phase 1 only)• EWSR1-WT1-positive DSRCTs (Phase 1 only)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001029-32-ITPyramid Biosciences74
进行中（未招募）
1 期
A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid TumorsEUCTR2021-001029-32-DKPyramid Biosciences91
进行中（未招募）
1 期
A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid TumorsEUCTR2021-001029-32-ESPyramid Biosciences74
终止
1 期
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid TumorsSolid Tumor, AdultBrain Tumor, PrimaryDesmoplastic Small Round Cell TumorNCT04901806Pyramid Biosciences29
已完成
2 期
A Study of Ibrutinib in Combination with Rituximab, in Japanese Participants with Waldenstrom's Macroglobulinemia (WM)JPRN-jRCT2080224857Janssen Pharmaceutical K.K.14